drugset
drugset / Trial / NCT06114745

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

NCT06114745 ↗

Phase 1 Completed 2 enrolled Atridia Pty Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.

Timeline

Start
2024-04-17
Primary completion
2025-07-08
Completion
2025-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1707 Monoclonal antibody — Intravenous

Indications

Alzheimer disease